[144] Rocket Pharmaceuticals, Inc. SEC Filing
Rocket Pharmaceuticals, Inc. (RCKT) notice reports proposed and recent insider transactions under Rule 144. An individual will offer 361 common shares held from a restricted stock vesting on 08/15/2025; the aggregate market value of the proposed sale is $1,081.63 and the shares are expected to be sold on 08/19/2025 on NASDAQ. The filing also discloses three prior sales by the same person during the past three months totaling 8,099 common shares for combined gross proceeds of $25,704.49. The filer attests they are unaware of any undisclosed material adverse information about the issuer.
Rocket Pharmaceuticals, Inc. (RCKT) segnala operazioni proposte e recenti da insider ai sensi della Regola 144. Un individuo offrir脿 361 azioni ordinarie risultanti da un vesting di azioni ristrette il 15/08/2025; il valore di mercato aggregato della vendita proposta 猫 di $1.081,63 e le azioni dovrebbero essere vendute il 19/08/2025 sul NASDAQ. La dichiarazione riporta anche tre vendite precedenti della stessa persona negli ultimi tre mesi per un totale di 8.099 azioni ordinarie, con proventi lordi complessivi di $25.704,49. Il dichiarante attesta di non essere a conoscenza di informazioni avverse materiali non divulgate sull'emittente.
Rocket Pharmaceuticals, Inc. (RCKT) informa sobre operaciones internas propuestas y recientes bajo la Regla 144. Una persona ofrecer谩 361 acciones ordinarias procedentes de un vesting de acciones restringidas el 15/08/2025; el valor de mercado agregado de la venta propuesta es de $1,081.63 y se espera que las acciones se vendan el 19/08/2025 en NASDAQ. El expediente tambi茅n revela tres ventas anteriores por la misma persona en los 煤ltimos tres meses por un total de 8,099 acciones ordinarias, con ingresos brutos combinados de $25,704.49. El declarante afirma no tener conocimiento de informaci贸n adversa material no divulgada sobre el emisor.
Rocket Pharmaceuticals, Inc. (RCKT)電� 攴滌箼 144鞐� 霐半ジ 鞝滌晥 氚� 斓滉芳 雮措秬鞛� 瓯半灅毳� 瓿奠頃╇媹雼�. 頃� 臧滌澑鞚� 2025-08-15鞐� 甓岆Μ頇曥爼(vesting)霅� 鞝滍暅欤检嫕鞐愳劀 361 氤错喌欤茧ゼ 鞝滉车頃� 鞓堨爼鞚措┌, 鞝滌晥霅� 毵り皝鞚� 齑� 鞁滉皜齑濎暋鞚� $1,081.63鞚搓碃 鞚� 欤检嫕霌れ潃 2025-08-19鞐� NASDAQ鞐愳劀 毵る弰霅� 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 鞝滌稖靹滌棎電� 臧欖潃 鞚鸽鞚� 歆�雮� 3臧滌洈 霃欖晥 齑� 8,099 欤茧ゼ 毵る弰頃� 齑� $25,704.49鞚� 齑濎垬鞚奠潉 鞓Π 靹� 瓯挫潣 鞚挫爠 毵る弰霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 氚滍枆須岇偓鞐� 甏�頃� 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞛堧嫟電� 靷嫟鞚� 鞎岇 氇豁暅雼り碃 歆勳垹頄堨姷雼堧嫟.
Rocket Pharmaceuticals, Inc. (RCKT) signale des op茅rations propos茅es et r茅centes d'initi茅s conform茅ment 脿 la R猫gle 144. Un individu offrira 361 actions ordinaires r茅sultant d'un vesting d'actions restreintes le 15/08/2025 ; la valeur de march茅 totale de la vente propos茅e est de 1 081,63 $ et les actions devraient 锚tre vendues le 19/08/2025 sur le NASDAQ. Le d茅p么t divulgue 茅galement trois ventes ant茅rieures par la m锚me personne au cours des trois derniers mois totalisant 8 099 actions ordinaires, pour des produits bruts combin茅s de 25 704,49 $. Le d茅clarant atteste ne pas avoir connaissance d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur.
Rocket Pharmaceuticals, Inc. (RCKT) meldet vorgeschlagene und k眉rzliche Insider-Transaktionen gem盲脽 Regel 144. Eine Person wird 361 Stammaktien anbieten, die aus einer Restricted-Stock-Vesting am 15.08.2025 stammen; der aggregierte Marktwert des geplanten Verkaufs betr盲gt $1.081,63 und die Aktien sollen am 19.08.2025 an der NASDAQ ver盲u脽ert werden. Die Einreichung offenbart au脽erdem drei fr眉here Verk盲ufe derselben Person innerhalb der letzten drei Monate in H枚he von insgesamt 8.099 Stammaktien mit zusammengerechnetem Bruttoerl枚s von $25.704,49. Der Melder erkl盲rt, ihm seien keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten bekannt.
- None.
- Insider sales totaling 8,099 shares for $25,704.49 in the past three months could attract investor attention despite being small relative to outstanding shares
- Planned immediate sale of 361 vested restricted shares indicates further insider disposition in the near term
Insights
Insider sold a small number of shares; transactions appear routine and immaterial to market capitalization.
The disclosed sales 鈥� 8,099 shares for $25,704.49 over the past three months plus a planned sale of 361 vested shares valued at $1,081.63 鈥� represent a vanishingly small fraction of the issuer's outstanding common stock (107,903,871 shares). From a market-impact perspective, these transactions are unlikely to affect share price or indicate major insider liquidity events. The origin of the planned sale is restricted stock vesting, which is a typical form of employee compensation and subsequent disposition.
Disclosure complies with Rule 144 norms; no governance red flags evident from the notice alone.
The filer provided required details including acquisition date, nature of acquisition (restricted stock vesting), and sales history. The signature attestation regarding material nonpublic information is included. There is no indication of unusual timing, related-party transfers, or concentrated block sales that would raise governance concerns. Absent other context, these are routine insider disposition disclosures.
Rocket Pharmaceuticals, Inc. (RCKT) segnala operazioni proposte e recenti da insider ai sensi della Regola 144. Un individuo offrir脿 361 azioni ordinarie risultanti da un vesting di azioni ristrette il 15/08/2025; il valore di mercato aggregato della vendita proposta 猫 di $1.081,63 e le azioni dovrebbero essere vendute il 19/08/2025 sul NASDAQ. La dichiarazione riporta anche tre vendite precedenti della stessa persona negli ultimi tre mesi per un totale di 8.099 azioni ordinarie, con proventi lordi complessivi di $25.704,49. Il dichiarante attesta di non essere a conoscenza di informazioni avverse materiali non divulgate sull'emittente.
Rocket Pharmaceuticals, Inc. (RCKT) informa sobre operaciones internas propuestas y recientes bajo la Regla 144. Una persona ofrecer谩 361 acciones ordinarias procedentes de un vesting de acciones restringidas el 15/08/2025; el valor de mercado agregado de la venta propuesta es de $1,081.63 y se espera que las acciones se vendan el 19/08/2025 en NASDAQ. El expediente tambi茅n revela tres ventas anteriores por la misma persona en los 煤ltimos tres meses por un total de 8,099 acciones ordinarias, con ingresos brutos combinados de $25,704.49. El declarante afirma no tener conocimiento de informaci贸n adversa material no divulgada sobre el emisor.
Rocket Pharmaceuticals, Inc. (RCKT)電� 攴滌箼 144鞐� 霐半ジ 鞝滌晥 氚� 斓滉芳 雮措秬鞛� 瓯半灅毳� 瓿奠頃╇媹雼�. 頃� 臧滌澑鞚� 2025-08-15鞐� 甓岆Μ頇曥爼(vesting)霅� 鞝滍暅欤检嫕鞐愳劀 361 氤错喌欤茧ゼ 鞝滉车頃� 鞓堨爼鞚措┌, 鞝滌晥霅� 毵り皝鞚� 齑� 鞁滉皜齑濎暋鞚� $1,081.63鞚搓碃 鞚� 欤检嫕霌れ潃 2025-08-19鞐� NASDAQ鞐愳劀 毵る弰霅� 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 鞝滌稖靹滌棎電� 臧欖潃 鞚鸽鞚� 歆�雮� 3臧滌洈 霃欖晥 齑� 8,099 欤茧ゼ 毵る弰頃� 齑� $25,704.49鞚� 齑濎垬鞚奠潉 鞓Π 靹� 瓯挫潣 鞚挫爠 毵る弰霃� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 氚滍枆須岇偓鞐� 甏�頃� 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞛堧嫟電� 靷嫟鞚� 鞎岇 氇豁暅雼り碃 歆勳垹頄堨姷雼堧嫟.
Rocket Pharmaceuticals, Inc. (RCKT) signale des op茅rations propos茅es et r茅centes d'initi茅s conform茅ment 脿 la R猫gle 144. Un individu offrira 361 actions ordinaires r茅sultant d'un vesting d'actions restreintes le 15/08/2025 ; la valeur de march茅 totale de la vente propos茅e est de 1 081,63 $ et les actions devraient 锚tre vendues le 19/08/2025 sur le NASDAQ. Le d茅p么t divulgue 茅galement trois ventes ant茅rieures par la m锚me personne au cours des trois derniers mois totalisant 8 099 actions ordinaires, pour des produits bruts combin茅s de 25 704,49 $. Le d茅clarant atteste ne pas avoir connaissance d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur.
Rocket Pharmaceuticals, Inc. (RCKT) meldet vorgeschlagene und k眉rzliche Insider-Transaktionen gem盲脽 Regel 144. Eine Person wird 361 Stammaktien anbieten, die aus einer Restricted-Stock-Vesting am 15.08.2025 stammen; der aggregierte Marktwert des geplanten Verkaufs betr盲gt $1.081,63 und die Aktien sollen am 19.08.2025 an der NASDAQ ver盲u脽ert werden. Die Einreichung offenbart au脽erdem drei fr眉here Verk盲ufe derselben Person innerhalb der letzten drei Monate in H枚he von insgesamt 8.099 Stammaktien mit zusammengerechnetem Bruttoerl枚s von $25.704,49. Der Melder erkl盲rt, ihm seien keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten bekannt.
FAQ
What insider transactions does the RCKT Form 144 disclose?
What was the source of the shares being sold under Rule 144 for RCKT?
On which exchange will the planned RCKT sale occur and when?
How large are these transactions relative to Rocket Pharmaceuticals' outstanding shares?
Does the Form 144 include an attestation about material nonpublic information?
Were any of the disclosed sales gifts or other nonstandard transfers?
